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Emergence of the OXA-23 carbapenemase-encoding gene in
multidrug-resistant Acinetobacter baumannii clinical isolates
from the Principal Hospital of Dakar, Senegal
Acinetobacter baumannii is an important opportunistic and
multidrug-resistant pathogen responsible for nosocomial infec-
tions in health facilities.1 Over the last 10 years, a signiﬁcant and
worrying increase in resistance to carbapenems in A. baumannii,
mainly due to dissemination of class D beta-lactamases, has been
reported worldwide.1 Although carbapenem resistance in A.
baumannii has been well studied worldwide, there are only few
data from Africa and none from Senegal.
Here we report the isolation and molecular characterization of
carbapenem resistance (imipenem minimum inhibitory concen-
trations (MICs) >32 mg/ml) in three clinical A. baumannii isolates
recovered in the Principal Hospital of Dakar, Senegal, between
September and October 2011 (Table 1). Bacterial isolation was
done while patients were receiving ceftriaxone, ciproﬂoxacin, or
imipenem (Table 1).
Carbapenemase activity was conﬁrmed using the modiﬁed
Hodge test as described previously.2 Identiﬁcation of A.
baumannii was conﬁrmed in Marseille, France, using MALDI-
TOF (matrix-assisted laser desorption ionization time-of-ﬂight)
mass spectrometry3 and partial sequencing of the rpoB gene.
Multilocus sequence typing (MLST) genotyping4 revealed that
the Ab_1 and Ab_4 strains had the same genotype, whereas the
Ab_5 strain had another genotype (data not shown). Molecular
detection of carbapenemase-encoding genes (OXA-51, OXA-23,
OXA-24, OXA-58, OXA-143, NDM-1, VIM, and IMP)5 showed that
the three imipenem-resistant isolates were positive only for the
blaOXA-23 carbapenemase-encoding gene and the constitutive
oxacillinase blaOXA-51 gene (Table 1). Sequencing of the blaOXA-23
gene showed an expected PCR product of 501 bp that was 100%
identical to that of the A. baumannii blaOXA-23 carbapenemase
gene (GenBank accession number JN207493). Furthermore,
investigation of the genetic support revealed that the associa-
Table 1
Genes found and antibiogram of the three Acinetobacter baumannii isolates in this
study
Isolate 1 Isolate 2 Isolate 3
Isolate
Strain Ab_1 Ab_4 Ab_5
Sample Blood BAL BAL
MSP score 2.1 2.16 2.03
Patient
Age 3 weeks 24 years 52 years
Sex F F M
Treatmenta IPM CRO CIP
Antibiogramb
TIC/PIP R R R
TIM/TZP R R R
CAZ/CRO R R R
IPMc R R R
CST S S S
GEN/TOB R R R
NET S S I
FOF R R R
CIP R R R
SXT R R R
ATM R R R
b-Lactamase genesd
blaOXA-23 + + +
blaOXA-51 + + +
ISAba1d
Alone + + +
ISAba1/OXA-23   +
ISAba1/OXA-51   
Ab, Acinetobacter baumannii; ATM, aztreonam; BAL, bronchoalveolar lavage; CAZ,
ceftazidime; CIP, ciproﬂoxacin; CRO, ceftriaxone; CST, colistin; F, female; FOF,
fosfomycin; GEN, gentamicin; IPM, imipenem; M, male; MSP score, MALDI-TOF
mass spectrometry score for bacterial identiﬁcation; NET, netilmicin; PIP,
piperacillin; SXT, trimethoprim–sulfamethoxazole; TIC, ticarcillin; TIM, ticarcil-
lin/clavulanic acid; TOB, tobramycin; TZP, piperacillin/tazobactam.
a Treatment received at the time of bacterial isolation.
b S, sensitive; I, intermediate; R, resistant.
c Imipenem MIC of these strains was > 32 mg/ml (Etest result).
d Positive (+) or negative () by standard PCR.
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negative for the Ab_1 and Ab_4 strains (Table 1). The insertion
sequence ISAba1 was not found in association with the blaOXA-51
gene.
In conclusion, to the best of our knowledge, the blaOXA-23
carbapenemase-encoding gene in A. baumannii has never been
reported in Senegal, and for Africa overall it has been reported
only in South Africa, Libya, Egypt, Tunisia, and Algeria.6,7 The
source of this gene and the route of dissemination remain to be
elucidated, but there is evidence that this gene can be detected
in the environment (air, soil, and water) and in body lice, as well
as in hospitals due to antibiotic selection pressure.1 The
emergence and spread of this gene in low-income countries is
worrying since infections due to A. baumannii are associated
with increased mortality as well as increased length of intensive
care unit stay.11201-9712/$36.00 – see front matter  2012 International Society for Infectious Disea
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